STOCK TITAN

Biora Therapeutics to Participate in Upcoming BTIG Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Biora Therapeutics (Nasdaq: BIOR) announced participation in one-on-one meetings at the BTIG Biotechnology Conference, held virtually and at the St. Regis New York Hotel on August 8-9, 2022. The company focuses on innovative drug delivery systems, particularly smart pills for targeted gastrointestinal treatment and needle-free biotherapeutics. Interested parties can schedule meetings through BTIG representatives. Biora aims to enhance patient care through advanced therapeutic solutions.

Positive
  • None.
Negative
  • None.

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022.

For those interested in meeting with Biora at the conference, please reach out to your BTIG representative to schedule a meeting.

About Biora Therapeutics
Biora Therapeutics is the biotech company that is reimagining therapeutics. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.

Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390

Media Contact
media@bioratherapeutics.com


FAQ

What is Biora Therapeutics' involvement in the BTIG Biotechnology Conference 2022?

Biora Therapeutics will participate in one-on-one meetings at the BTIG Biotechnology Conference held on August 8-9, 2022.

Where is the BTIG Biotechnology Conference taking place?

The conference is being held virtually and at the St. Regis New York Hotel.

How can I meet with Biora Therapeutics during the conference?

Interested individuals should contact their BTIG representative to schedule a meeting with Biora Therapeutics.

What innovative therapies does Biora Therapeutics develop?

Biora Therapeutics develops smart pills for targeted drug delivery and needle-free delivery systems for biotherapeutics.

What is the main goal of Biora Therapeutics?

Biora Therapeutics aims to improve patient outcomes through innovative drug delivery solutions.

Biora Therapeutics, Inc.

NASDAQ:BIOR

BIOR Rankings

BIOR Latest News

BIOR Stock Data

994.99k
4.52M
0.1%
36%
6.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO